Singapore Dermatological Therapeutics Market Report 2022 to 2030

Singapore Dermatological Therapeutics Market Analysis

$ 3999

Singapore Dermatological Therapeutics Market is at around $0.05 Bn in 2023 and is projected to reach $0.09 Bn in 2030, exhibiting a CAGR of 9.2% during the forecast period. The market is expanding as a result of the prevalence of skin conditions, rising awareness, and consumer preferences for aesthetic procedures. The market is dominated by key players like Almirall SA, Pfizer Inc., GlaxoSmithKline Plc, AbbVie Inc., Amgen Inc., Novartis AG, Roche, Sanofi, Bayer, and Johnson & Johnson.

ID: IN10SGPH035 CATEGORY: Pharmaceuticals GEOGRAPHY: Singapore AUTHOR: Aneri Parekh

Buy Now

Singapore Dermatological Therapeutics Market Executive Summary

Singapore Dermatological Therapeutics Market is at around $0.05 Bn in 2023 and is projected to reach $0.09 Bn in 2030, exhibiting a CAGR of 9.2% during the forecast period.

Singapore Dermatological Therapeutics explores advanced and comprehensive dermatological techniques in the context of Singapore's evolving healthcare system. This includes using state-of-the-art therapy approaches, creative therapies, and technological integration to treat a variety of skin diseases. The area highlights Singapore's dedication to providing high-quality dermatological treatment, placing a strong emphasis on patient-centered solutions, and leading the way in worldwide advances in skin therapies.

Due to growing awareness of skin health and aesthetic issues, the Singapore Dermatological Therapeutics Market is expanding steadily. The need for dermatological treatments is further fueled by an aging population and an increase in the prevalence of skin disorders. Prominent industry participants prioritize innovation and tactical partnerships to augment their product portfolios and sustain a competitive advantage.

By 2023, the global market for dermatological treatments brought in $40.94 Bn, a significant rise from the year before. Modern production techniques and low-cost technology are driving this revolution in the industry. The market for dermatological treatments has become a thriving and expanding industry due to the dynamic combination of accessibility, innovation, and financial aid.

Pfizer is a major player in Singapore's dermatological therapeutics market, specializing mostly in treating atopic dermatitis, a chronic inflammatory skin disease. Pfizer released favorable top-line results from the JADE COMPARE trial in August 2023, demonstrating notable improvements in individuals with moderate-to-severe atopic dermatitis in terms of skin clearance, disease extent and severity, and itching.

Singapore dermatological therapeutics market

Market Dynamics

Market Growth Drivers:

Prevalence of Skin Conditions: The need for dermatological therapies is driven by the prevalence of dermatological conditions in the country. Several factors, including alterations in lifestyle and pollution, are raising the incidence of skin conditions.

Increasing Awareness: The availability of cutting-edge dermatological therapies and rising consumer knowledge of skincare issues are supporting the market expansion. In this context, information sharing, educational initiatives, and awareness campaigns can be quite helpful.

Customer Preferences for Aesthetic Procedures: The demand for dermatological treatments is fuelled by the expanding trend of aesthetic operations for cosmetic purposes.

Market Restraints:

Cost of Treatment: The adoption of dermatological treatments is dependent upon affordability. Certain populations may not be able to get therapies if they are too expensive.

Competitive Market: Intense competition among pharmaceutical companies could lead to lower profit margins and pressure on prices, which would hinder the expansion of the dermatological treatments industry.

Global Economic Factors: Consumer spending on healthcare may be impacted by economic downturns or uncertainty, which could have an impact on the market for dermatological therapies.

Healthcare Policies and Regulatory Landscape

The Health Sciences Authority (HSA) is the name of the statutory board under the Ministry of Health in Singapore. It is a multidisciplinary organization whose job it is to protect and enhance public health and safety by applying knowledge in medicine, pharmacy, and science. The drug's quality, safety, and efficacy will all be assessed as part of the technical review of the application by the HSA. The screening procedure may take up to 180 working days. The HSA adheres to strict quality, safety, and efficacy standards in compliance with international standards (ICH). This could lead to rigorous and time-consuming criteria for pre-clinical and clinical trials, particularly for novel drugs.

Competitive Landscape

Key Players:

Almirall SA
Pfizer Inc.
GlaxoSmithKline Plc.
AbbVie Inc.
Amgen Inc.
Novartis AG
Roche
Sanofi
Bayer
Johnson & Johnson

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Singapore Dermatological Therapeutics Market Segmentation

By Type

Prescription-based Drugs
Over-the-counter Drugs

By Disease

Alopecia
Herpes
Psoriasis
Rosacea
Skin Cancer
Acne
Atopic Dermatitis
Vitiligo
Hidradenitis
Other Applications

By Drug Class

Anti-infectives
Corticosteroids
Anti-acne
Calcineurin Inhibitors
Retinoids
Other Drug Classes

By Route of Administration

Topical Administration
Oral Administration
Parenteral Administration

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.